Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders

Journal of Clinical Psychopharmacology

Volumn 17, Issue 5, 1997, Pages 407-418

  Tran, Pierre V ^a   Hamilton, Susan H ^a   Kuntz, Amy J ^a   Potvin, Janet H ^a   Andersen, Scott W ^a   Beasley Jr , Charles ^a   Tollefson, Gary D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; NIGHTMARE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOIDISM; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; VISUAL IMPAIRMENT; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PIRENZEPINE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; QUALITY OF LIFE; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0030770872     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199710000-00010     Document Type: Article

References (53)

1. Kane J. The current status of neuroleptics. J Clin Psychiatry 1989;50:322-8.
2. Kane JMS. Schizophrenia. N Engl J Med 1996;334:34-41.
3. Corrigan PW, Liberman RP, Engel JD. From noncompliance to collaboration in the treatment of schizophrenia. Hosp Community Psychiatry 1990;41:1203-11.
4. Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic noncompliance. Psychiatric Ann 1986;16:571-5.
5. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-87.
6. Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 1996; 124:2-34.
7. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996;124:57-73.
8. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, Seeman P, Wong DT. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
9. Beasley CM Jr, Tollefson GD, Tran P, Satterlee W, Sanger T, Hamilton S. The Olanzapine HGAD Study Group. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:105-18.
10. Beasley CM, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine HGAP Study Group. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-67.
11. Chouinard G, Jones B, Remington G, Bloom D, Addington D, McEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed-doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
12. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
13. Peuskens J. The Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
14. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Tamura RN, Krueger JA, Graffeo KA, Thieme ME. Olanzapine versus haloperidol in the treatment of schizophrenia, schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997;154:457-65.
15. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-74.
16. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994;268:1403-10.
17. Cools AR, Prinssen EPM, Ellenbroek BA. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology 1995;119:428-39.
18. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW. Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 1995;120:67-74.
19. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol 1995;281:289-94.
20. Moore NA, Rees G, Sanger G, Tye NC. Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 1994;5:196-202.
21. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 1992;262:545-51.
22. Bakshi VP, Geyer MA. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology 1995;122:198-201.
23. 2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 1231 IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996;124:148-53.
24. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of neuroleptic-induced fos-like immunoreactivity as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 1994;271: 1058-66.
25. Robertson GS, Fibiger HC. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology 1996;14: 105-10.
26. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261-76.
27. Guy W. ECDEU assessment manual for psychopharmacology. Rev ed. Bethesda, MD: US Department of Health, Education and Welfare, 1976:217-22.
28. Andreasen NC. The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 1989;155:S49-S52.
29. US Food and Drug Administration. COSTART coding symbols for thesaurus of adverse reaction Terms. 2nd ed. Rockville, MD: Food and Drug Administration, 1990.
30. Arbeltsgemelnschaft fur Methodik und Dokumentation in der Psychiatrie. (Association for Methodology and Documentation in Psychiatry [AMDP]). Das AMDP-System. Manual zur Dokumentation psychiatrischer Befunde. 4th Auflage. Berlin: AMDP, 1981.
31. Guy W, Ban TA, eds. The AMDP system. Berlin: Springer, 1982.
32. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:S11-S19.
33. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
34. Guy W. ECDEU assessment manual for psychopharmacology. Rev ed. Bethesda, MD: US Department of Health, Education and Welfare, 1976:534-7.
35. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98.
36. Schooler NM, Kane JM. Research diagnosis for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982;39:486-7.
37. Lee ET. Statistical methods for survival data analysis. 2nd ed. New York: Wiley Interscience, 1992.
38. SAS Institute, Inc. SAS/STAT user's guide, vols. 1 & 2. 4th ed., version 6. Cary, NC: SAS Institute, Inc., 1990.
39. Buchanan RW, Brandes M, Breier A. Treating negative symptoms: pharmacological strategies. In: Breier A, ed. The new pharmacotherapy of schizophrenia. Washington, DC: American Psychiatric Association Press, 1996:179-204.
40. Moller HJ, Muller H, Borison RL, Schooler NR, Chouinard G. A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 1995;245:45-9.
41. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC. Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 1994;35:8-15.
42. Miles CP. Conditions predisposing to suicide: a review. J Nerv Ment Dis 1977;164:231-46.
43. Fenton WS, McGlashan TH, Victor BJ, Blyler CR. Symptoms, subtype, and suicidality in patients with schizophrenia spectrum disorders. Am J Psychiatry 1997;154:199-204.
44. Wyatt RJ, Henter I, Leary MC, Taylor E. An economic evaluation of schizophrenia - 1991. Soc Psychiatry Psychiatr Epidemiol 1995;30:196-205.
45. Malhotra AK, Pinsky DA, Breier A. Future antipsychotic agents: clinical implications. In: Breier A, ed. The new pharmacotherapy of schizophrenia. Washington, DC: American Psychiatric Association Press, 1996:41-56.
46. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol 1997;17: 194-201.
47. Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 1988; 8[suppl 4]:21S-26S.
48. Siris SG. Treatment of depression in patients with schizophrenia. In: Breier A, ed. The new pharmacotherapy of schizophrenia. Washington, DC: American Psychiatric Association Press, 1996:205-21.
49. Gelenberg AJ. Psychoses. In: Bassuk EL, Schoonover SC, Gelenberg AJ, eds. The practitioner's guide to psychoactive drugs. 2nd ed. New York: Plenum Medical Book Company, 1983:115-55.
50. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995;56:137-41.
51. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic out-patients. J Nerv Ment Dis 1982;170:463-7.
52. Seagraves RT. Effects of psychotropic drugs on human erection and ejaculation. Arch Gen Psychiatry 1989;46:275-84.
53. Marder SR. Clinical experience with risperidone. J Clin Psychiatry 1996;57:57S-61S.